ArticlemAbs2020
Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study.
Article in mAbs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Purification of Advanced Therapeutics by Flow-Through Pseudo-Affinity Chromatography: Bi-Specific mABs, Fc Fusion Proteins, and Adeno-Associated Viruses.Biotechnology and bioengineering · 2026Article
- TiOBioprocess and biosystems engineering · 2026Article
- Revisiting the streptococcal M protein: modern perspectives on antibody function, host interactions, and therapeutic targeting.Frontiers in immunology · 2026Review
- Developing affordable monoclonal antibodies for LMICs through high performance manufacturing processes and LMIC based commercial manufacturing.Frontiers in pediatrics · 2026Article
- Development of Cell Culture Media for Cultivated Meat Production.Advances in biochemical engineering/biotechnology · 2026Review
- The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.Frontiers in bioengineering and biotechnology · 2026Review
- Review
- Comparative Approaches for Quantification of Product Yield in the Production of Recombinant Green Fluorescent Protein (GFPuv) Expressed inbioRxiv : the preprint server for biology · 2025Article
- Cell specific perfusion rates drive growth dynamics and metabolism in CHO N-1 perfusion processes independent of perfusion rate control method.Frontiers in bioengineering and biotechnology · 2025Article
- Exploration of alternative microfiltration modalities for the harvest and clarification of diverse recombinant proteins from high-density E. coli culture and lysate using hollow fibre, flat sheet cassette, and vibro membrane filtration technologies.Journal of industrial microbiology & biotechnology · 2024Article
- Computational framework for the techno-economic analysis of monoclonal antibody capture chromatography platforms.Journal of chromatography. A · 2023Article
- Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-Cloning.Bioengineering (Basel, Switzerland) · 2022Article
- N-1 Perfusion Platform Development Using a Capacitance Probe for Biomanufacturing.Bioengineering (Basel, Switzerland) · 2022Article
- Rapid intensification of an established CHO cell fed-batch process.Biotechnology progress · 2022Article
- AAV process intensification by perfusion bioreaction and integrated clarification.Frontiers in bioengineering and biotechnology · 2022Article
- End-to-end collaboration to transform biopharmaceutical development and manufacturing.Biotechnology and bioengineering · 2021Review
- Applications and analysis of hydrolysates in animal cell culture.Bioresources and bioprocessing · 2021Review
- Techno-economic analysis of membrane-based continuous capture chromatography platforms for large-scale antibody production.Biotechnology progressArticle
- Machine learning-assisted clone selection for intensified cell culture processes.Biotechnology progressArticle
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Process intensification has shown great potential to increase productivity and reduce costs in biomanufacturing. This case study describes the evolution of a manufacturing process from a conventional processing scheme at 1000-L scale (Process A, n = 5) to intensified processing schemes at both 1000-L (Process B, n = 8) and 2000-L scales (Process C, n = 3) for the production of a monoclonal antibody by a Chinese hamster ovary cell line. For the upstream part of the process, we implemented an intensified seed culture scheme to enhance cell densities at the seed culture step (N-1) prior to the production bioreactor (N) by using either enriched N-1 seed culture medium for Process B or by operating the N-1 step in perfusion mode for Process C. The increased final cell densities at the N-1 step allowed for much higher inoculation densities in the production bioreactor operated in fed-batch mode and substantially increased titers by 4-fold from Process A to B and 8-fold from Process A to C, while maintaining comparable final product quality. Multiple changes were made to intensify the downstream process to accommodate the increased titers. New high-capacity resins were implemented for the Protein A and anion exchange chromatography (AEX) steps, and the cation exchange chromatography (CEX) step was changed from bind-elute to flow-through mode for the streamlined Process B. Multi-column chromatography was developed for Protein A capture, and an integrated AEX-CEX pool-less polishing steps allowed semi-continuous Process C with increased productivity as well as reductions in resin requirements, buffer consumption, and processing times. A cost-of-goods analysis on consumables showed 6.7-10.1 fold cost reduction from the conventional Process A to the intensified Process C. The hybrid-intensified process described here is easy to implement in manufacturing and lays a good foundation to develop a fully continuous manufacturing with even higher productivity in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.